131 related articles for article (PubMed ID: 11223827)
21. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
O'Connell J; Bennett MW; O'Sullivan GC; Roche D; Kelly J; Collins JK; Shanahan F
J Pathol; 1998 Nov; 186(3):240-6. PubMed ID: 10211111
[TBL] [Abstract][Full Text] [Related]
22. Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer.
Zheng HC; Sun JM; Wei ZL; Yang XF; Zhang YC; Xin Y
World J Gastroenterol; 2003 Jul; 9(7):1415-20. PubMed ID: 12854132
[TBL] [Abstract][Full Text] [Related]
23. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.
Kusaba T; Nakayama T; Yamazumi K; Yakata Y; Yoshizaki A; Nagayasu T; Sekine I
J Clin Pathol; 2005 Aug; 58(8):833-8. PubMed ID: 16049285
[TBL] [Abstract][Full Text] [Related]
24. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y
Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580
[TBL] [Abstract][Full Text] [Related]
25. Reduced p16 expression correlates with lymphatic invasion in colorectal cancers.
Tada T; Watanabe T; Kazama S; Kanazawa T; Hata K; Komuro Y; Nagawa H
Hepatogastroenterology; 2003; 50(54):1756-60. PubMed ID: 14696398
[TBL] [Abstract][Full Text] [Related]
26. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic and immunohistochemical study of small apparently "de novo" colorectal adenocarcinomas.
Hornick JL; Farraye FA; Odze RD
Am J Surg Pathol; 2007 Feb; 31(2):207-15. PubMed ID: 17255765
[TBL] [Abstract][Full Text] [Related]
28. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
29. Fas/FasL expression in colorectal cancer. An immunohistochemical study.
Pryczynicz A; Guzińska-Ustymowicz K; Kemona A
Folia Histochem Cytobiol; 2010 Sep; 48(3):425-9. PubMed ID: 21071349
[TBL] [Abstract][Full Text] [Related]
30. [Expression of Fas ligand on peritumoral lymphocytes and its association with apoptosis of colorectal carcinomas].
Song E; Chen J; Wang J; Zhang L
Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):517-9, 29. PubMed ID: 11832097
[TBL] [Abstract][Full Text] [Related]
31. Expression of cyclin E in colorectal adenomas and adenocarcinomas: correlation with expression of Ki-67 antigen and p53 protein.
Yasui W; Kuniyasu H; Yokozaki H; Semba S; Shimamoto F; Tahara E
Virchows Arch; 1996 Sep; 429(1):13-9. PubMed ID: 8865848
[TBL] [Abstract][Full Text] [Related]
32. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
33. [Detection of proliferative cells in colorectal carcinomas and adenomas by monoclonal antibody to DNA polymerase alpha].
Okano S; Obara T; Okuyama S; Takemura K; Saito Y; Ura H; Ashida T; Ayabe T; Shibata Y; Okamura K
Nihon Shokakibyo Gakkai Zasshi; 1990 Nov; 87(11):2444-50. PubMed ID: 2277435
[TBL] [Abstract][Full Text] [Related]
34. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.
Xu LN; Zou SQ; Wang JM
World J Gastroenterol; 2005 Jun; 11(24):3719-23. PubMed ID: 15968727
[TBL] [Abstract][Full Text] [Related]
35. Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers.
Alqurashi N; Gopalan V; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2089-96. PubMed ID: 23773481
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma.
Furudoi A; Tanaka S; Haruma K; Yoshihara M; Sumii K; Kajiyama G; Shimamoto F
Oncology; 2001; 60(2):162-9. PubMed ID: 11244332
[TBL] [Abstract][Full Text] [Related]
37. Expression of interleukin-11 and interleukin-11 receptor alpha in human colorectal adenocarcinoma; immunohistochemical analyses and correlation with clinicopathological factors.
Yamazumi K; Nakayama T; Kusaba T; Wen CY; Yoshizaki A; Yakata Y; Nagayasu T; Sekine I
World J Gastroenterol; 2006 Jan; 12(2):317-21. PubMed ID: 16482637
[TBL] [Abstract][Full Text] [Related]
38. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
39. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
[TBL] [Abstract][Full Text] [Related]
40. [The role of Fas/FasL system in the regulation of tumor-immune system interactions in papillary thyroid carcinoma in children and adolescents].
Portianko AS; Cherstvoĭ ED
Arkh Patol; 2003; 65(4):18-21. PubMed ID: 14518188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
